{"disease":{"id":"inoperable-or-recurrent-breast-cancer","name":"inoperable or recurrent breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01463891","title":"Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}